ReviewFrontiers in microbiology2018
Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites.
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 74 citations in OpenAlex.
- Manipulation of host response and trajectory of parasite survival: A damage-response framework perspective.Virulence · 2026Review
- Design, Synthesis, and Antileishmanial Activity of Novel C6-Substituted Eugenol Derivatives with a Triazole Linker.ACS omega · 2026Article
- Vitamin DApplied microbiology and biotechnology · 2026Review
- Convergence in Coevolved Systems: A Two-Axis Filter for Biomimetic Transferability.Biomimetics (Basel, Switzerland) · 2026Article
- Emerging host-directed strategies for overcoming drug resistance and immune evasion in Staphylococcus aureus infections.Journal of advanced research · 2026Review
- Targeting mitochondrial bioenergetics: the "Achilles' heel" of Leishmania.Parasites & vectors · 2026Article
- Exploiting host kinases to combat dengue virus infection and disease.Antiviral research · 2025Review
- The emerging role of Imatinib in malaria management: a review of evidence and future directions.Tropical diseases, travel medicine and vaccines · 2025Review
- Therapeutic potential of Indonesian plant extracts in combating malaria and protozoan neglected tropical disease.BMC complementary medicine and therapies · 2024Article
- Aminopyridines in the development of drug candidates against protozoan neglected tropical diseases.Future medicinal chemistry · 2024Review
- Future applications of host direct therapies for infectious disease treatment.Frontiers in immunology · 2024Review
- Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.Nature communications · 2023Article
- Quinoxalines against Leishmania amazonensis: SAR study, proposition of a new derivative, QSAR prediction, synthesis, and biological evaluation.Scientific reports · 2023Article
- Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies.International journal of molecular sciences · 2023Review
- Generation of Aurachin Derivatives by Whole-Cell Biotransformation and Evaluation of Their Antiprotozoal Properties.Molecules (Basel, Switzerland) · 2023Article
- State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation.Research and reports in tropical medicine · 2023Review
- Thio- and selenosemicarbazones as antiprotozoal agents againstJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Effects of Structurally Different HDAC Inhibitors againstACS infectious diseases · 2022Article
- Innate immune cell response to host-parasite interaction in a human intestinal tissue microphysiological system.Science advances · 2022Article
- Antiparasitic Effects of Sulfated Polysaccharides from Marine Hydrobionts.Marine drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The neglected tropical diseases (NTDs) caused by protozoan parasites are responsible for significant morbidity and mortality worldwide. Current treatments using anti-parasitic drugs are toxic and prolonged with poor patient compliance. In addition, emergence of drug-resistant parasites is increasing worldwide. Hence, there is a need for safer and better therapeutics for these infections. Host-directed therapy using drugs that target host pathways required for pathogen survival or its clearance is a promising approach for treating infections. This review will give a summary of the current status and advances of host-targeted therapies for treating NTDs caused by protozoa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.